167 related articles for article (PubMed ID: 38161697)
21. TNFR2: Role in Cancer Immunology and Immunotherapy.
Yang Y; Islam MS; Hu Y; Chen X
Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
[TBL] [Abstract][Full Text] [Related]
22. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
[TBL] [Abstract][Full Text] [Related]
23. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
24. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
25. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
[TBL] [Abstract][Full Text] [Related]
26. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice.
Zhang C; Lei L; Yang X; Ma K; Zheng H; Su Y; Jiao A; Wang X; Liu H; Zou Y; Shi L; Zhou X; Sun C; Hou Y; Xiao Z; Zhang L; Zhang B
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34642245
[TBL] [Abstract][Full Text] [Related]
27. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
29. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
[TBL] [Abstract][Full Text] [Related]
30. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
31. Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+ T regulatory cells.
Guo Y; Xie F; Liu X; Ke S; Chen J; Zhao Y; Li N; Wang Z; Yi G; Shen Y; Li D; Zhu C; Zhang Z; Zhao G; Lu H; Li B; Zhao W
J Mol Cell Biol; 2023 Nov; ():. PubMed ID: 37935468
[TBL] [Abstract][Full Text] [Related]
32. Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer.
Zhu L; Zhang X; Chen X; Yang D; Nie Y; Pan R; Li L; Wang C; Gui H; Chen S; Jing Q; Wang M; Nie Y
Biochem Biophys Res Commun; 2023 Apr; 653():106-114. PubMed ID: 36868074
[TBL] [Abstract][Full Text] [Related]
33. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
35. The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.
Moatti A; Cohen JL
Front Cell Dev Biol; 2021; 9():725473. PubMed ID: 34712661
[TBL] [Abstract][Full Text] [Related]
36. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
38. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
39. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.
Ramamoorthi G; Kodumudi K; Snyder C; Grover P; Zhang H; Greene MI; Basu A; Gallen C; Wiener D; Costa RLB; Han HS; Koski G; Czerniecki BJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
